FINWIRES · TerminalLIVE
FINWIRES

$NVO

67 stories mentioning NVO

Every FINWIRES story that references NVO, newest first.

US Markets

Stocks Rise Pre-Bell, Oil Prices Fall After Report Says US, Iran Nearing Peace Agreement

The main US stock measures were pointing higher in Wednesday's premarket activity, while oil prices declined after a media report said the US and Iran are nearing a potential agreement to end their conflict.The S&P 500 and the Dow Jones Industrial Average rose 0.7% each before the opening bell, while the Nasdaq advanced 1.2%. The indexes finished the previous trading session in the green, with the S&P 500 and the Nasdaq closing with new highs.Washington is nearing an agreement with Tehran on a one-page memorandum of understanding to end their conflict in the Middle East and establish a framework for more detailed nuclear negotiations, Axios reported Wednesday, citing two US officials and two other sources familiar with the matter.In a social media post on Tuesday, President Donald Trump said the US is temporarily pausing "Project Freedom," its effort to guide neutral ships locked up in the Strait of Hormuz out of the crucial waterway. Trump noted that the US blockade on Iranian ports will remain in effect.US Defense Secretary Pete Hegseth reportedly said Tuesday that the ceasefire agreement with Iran remained intact despite recently renewed tensions in the Gulf region.West Texas Intermediate crude oil dropped 9.3% to $92.88 a barrel in premarket action, while Brent fell 8.3% to $100.77.Treasury yields slipped before the open, with the two-year rate retreating 7.3 basis points to 3.87% and the 10-year rate off 6.8 basis points to 4.35%.Walt Disney (DIS), Uber Technologies (UBER), CVS Health (CVS), Marriott International (MAR), Johnson Controls International (JCI), Restaurant Brands International (QSR), Kraft Heinz (KHC) and Performance Food Group (PFGC) are some of the major companies scheduled to report their latest financial results before the bell, among others.Arm Holdings (ARM), Applovin (APP), DoorDash (DASH) and Warner Bros. Discovery (WBD) post earnings after the markets close.Shares of Advanced Micro Devices (AMD) jumped 18% pre-bell after the chipmaker reported stronger-than-expected first-quarter results. Novo Nordisk's (NVO) US-listed stock climbed 7.5% as the Danish pharmaceutical giant issued an improved full-year sales outlook. Arista Networks (ANET) declined 8.1% after it issued a downbeat second-quarter revenue outlook.Wednesday's economic calendar has the weekly mortgage applications bulletin at 7 am ET, followed by the ADP Employment report for April at 8:15 am. The weekly EIA domestic petroleum inventories report is out at 10:30 am.Federal Reserve Bank of St. Louis President Alberto Musalem is slated to speak at 9:30 am, while Chicago Fed President Austan Goolsbee speaks at 1 pm.Gold increased 3.1% to $4,710 per troy ounce, while bitcoin moved up 0.8% to $82,210.

Dow JonesNasdaq CompositeS&P 500$AMD$ANET$APP$ARM$CVS$DASH$DIS$JCI$KHC$MAR$NVO$PFGC$QSR$UBER$WBD
Research

Research Alert: Novo Nordisk Raises 2026 Outlook On Strong Wegovy Pill Sales

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Reported Q1 sales and operating profit surged 24% and 54%, respectively, boosted by a $4.2B reversal of 340B Drug Pricing Program rebate provision. On an adjusted basis (excluding this item), sales declined 10% (or -4% CER) due to lower realized prices, particularly in the U.S., partially offset by volume growth. The Wegovy pill, launched in January, delivered DKK2.3B in Q1 sales with weekly prescriptions exceeding 200k by mid-April and 2M+ total prescriptions, while injectable Wegovy grew 12% CER internationally, though U.S. sales fell 11% CER on pricing pressure. Management raised its 2026 outlook, with adjusted sales and operating profit now expected to decline 4%-12% CER (vs. prior -5% to -13%), reflecting stronger GLP-1 expectations, particularly for the Wegovy pill. Wegovy pill's strong launch trajectory is encouraging, with international rollout expected in 2H 2026. However, persistent U.S. pricing pressure, mixed clinical data (CagriSema setbacks), and intensifying competition warrant close monitoring.

$NVO
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Friday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.4%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 1.4%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 4.9%.Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said. Lilly shares rose 3.1%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.9%.

$AMGN$LLY$MRNA$NVO
Sectors

Sector Update: Health Care Stocks Softer Friday Afternoon

Health care stocks fell Friday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 2.9%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 5.6%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.2%.

$AMGN$MRNA$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

European equities traded in the US as American depositary receipts were trending marginally higher late Friday morning, rising 0.05% to 1,824.45 on the S&P Europe Select ADR Index, which is up 1.25% for the week so far.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and pharmaceutical company Novo Nordisk (NVO), which climbed 6.3% and 3.6% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and consumer goods company Unilever (UL), which advanced 3.3% and 3% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and furniture maker Natuzzi (NTZ), which dropped 6% and 3.5% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which lost 3.3% and 2.4% respectively.The gainers from the UK were led by educational publisher Pearson (PSO) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 3.2% and 2.8% respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and cruise line operator Carnival (CUK), which were up 2.7% and 2.5% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Amarin (AMRN) and oil and gas company BP (BP), which fell 2.8% and 1.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and oil and gas company Shell (SHEL), which were down 1.4% and 1.2% respectively.

$AKTX$AMRN$BCYC$BDRX$BNTX$BP$CLLS$CUK$DBVT$EQNR$NOK$NTZ$NVO$PSO$SHEL$UL
Sectors

Sector Update: Health Care Stocks Advance Pre-Bell Friday

Health care stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.2%.Novo Nordisk (NVO) shares were up more than 2% after the company said it has rebranded its oral semaglutide medication for type 2 diabetes, formerly known as Rybelsus, as Ozempic.Veeva Systems (VEEV) is set to join the S&P 500 on May 7, to replace Coterra Energy (CTRA), S&P Dow Jones Indices said. Shares of Veeva Systems were up more than 11% premarket.Moderna (MRNA) stock was up more than 2% after the company reported a narrower-than-expected Q1 net loss.

$CTRA$IBB$MRNA$NVO$VEEV$XLV
Sectors

Sector Update: Health Care

Health care stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.2%.Novo Nordisk (NVO) shares were up more than 2% after the company said it has rebranded its oral semaglutide medication for type 2 diabetes, formerly known as Rybelsus, as Ozempic.

$NVO
Sectors

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.Axsome Therapeutics (AXSM) shares surged 12% after it said the US Food and Drug Administration approved Auvelity to treat agitation associated with Alzheimer's disease dementia.Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped past 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose past 5%.

$AXSM$LLY$NVO$QURE
Sectors

Sector Update: Health Care Stocks Gain Thursday Afternoon

Health care stocks rose Thursday afternoon with the NYSE Health Care Index climbing 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 2%.In corporate news, Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose 5.0%.NovoCure (NVCR) shares surged 28% after the company posted Q1 results.

$LLY$NVCR$NVO
Wire

Update: FDA Seeks to Exclude Tirzepatide, Semaglutide, Liraglutide From 503B Bulks List

(Updates with Lilly's comment in the third paragraph.)The US Food and Drug Administration said Thursday it is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances.Eli Lilly (LLY) manufactures tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) manufactures semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management.In an emailed statement to, Lilly said it is "pleased FDA has confirmed there is no clinical need for compounded tirzepatide. That means there is no basis for compounders to make tirzepatide knockoffs. Lilly will continue working to protect patients from the risks associated with unapproved drugs prescribed without a medical need."Under federal law, outsourcing facilities generally cannot compound drugs from bulk substances unless the ingredient appears on the 503B bulks list or the compounded drug is on the FDA's drug-shortage list at the time of compounding, distribution and dispensing, the agency said.The FDA is accepting public comments on the proposal through June 29.Novo Nordisk didn't immediately reply to a request for comment from.Lilly shares jumped 9.8% in Thursday trading, and Novo Nordisk gained 5.7%Price: $934.57, Change: $+83.36, Percent Change: +9.79%

$LLY$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

European equities traded in the US as American depositary receipts rose late Thursday morning, gaining 2.20% to 1,818.51 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and lender ING Groep (ING), which advanced 5.3% and 4.9% respectively. They were followed by biopharmaceutical firm Grifols (GRFS) and consumer goods firm Unilever (UL), which rose 3.2% and 3.1% respectively.The decliners from continental Europe were led by internet advertising firm Criteo (CRTO) and telecommunications company Nokia (NOK), which fell 3.2% and 1.9% respectively.The gainers from the UK were led by cruise line operator Carnival (CUK) and utilities company National Grid (NGG), which rose 4.8% and 3.5% respectively. They were followed by Lloyds Banking Group (LYG) and telecommunications operator Vodafone Group (VOD), which were up 2.6% and 2.3% respectively.The decliners from the UK and Ireland were led by software firm Endava (DAVA) and Bicycle Therapeutics (BCYC), which lost 5.2% and 2.3% respectively. They were followed by biopharmaceutical companies Amarin (AMRN) and Mereo BioPharma Group (MREO), which fell 1.3% and 0.9% respectively.

$AMRN$BCYC$CRTO$CUK$DAVA$GRFS$ING$LYG$MREO$NGG$NOK$NVO$UL$VOD
Wire

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List

The US Food and Drug Administration said Thursday it is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances.Novo Nordisk (NVO) manufactures semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Eli Lilly (LLY) manufactures tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.Normally, outsourcing facilities cannot compound drugs using bulk drug substances unless the substance is on the 503B bulks list or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing, the FDA said.Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from.Price: $42.48, Change: $+2.19, Percent Change: +5.44%

$LLY$NVO
Wire

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List

$LLY$NVO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline Tuesday

European equities traded in the US as American depositary receipts were lower on Tuesday morning, down 0.3% to 1,784.71 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by technology company Opera (OPRA) and telecoms, information technology, and consumer electronics corporation Nokia (NOK), which climbed 7.8% and 1.4% respectively.They were followed by pharmaceutical giant Novo Nordisk (NVO), which added 1%.The decliners from continental Europe were led by semiconductor companies Sequans Communications (SQNS) and ASML (ASML), which fell 6.2% and 4.7% respectively.They were followed by solar energy technology company Turbo Energy (TURB), which shed 3.7%.From the UK and Ireland, the gainers were led by clinical-stage biopharmaceutical company Autolus Therapeutics (AUTL), which rose 3.2%, followed by oil and gas companies Shell (SHEL) and BP (BP), which advanced 1.3% and 1.1% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm (ARM) and budget airline Ryanair (RYAAY), which dropped 8.9% and 2.4% respectively.

$ARM$ASML$AUTL$BP$NOK$NVO$OPRA$RYAAY$SHEL$SQNS$TURB
Asia Markets

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

European equities traded in the US as American depositary receipts were rising late Friday morning, gaining 0.66% at 1,798.36 on the S&P Europe Select ADR Index, which is off 2% for the week so far.From continental Europe, the gainers were led by pharmaceutical company Novo Nordisk (NVO) and software firm SAP (SAP), which rose 6.4% and 5.6% respectively. They were followed by furniture maker Natuzzi (NTZ) and consumer goods company Unilever (UL), which were up 2.6% and 1.7% respectively.The decliners from continental Europe were led by biotech firm Evaxion (EVAX) and petroleum refiner Equinor (EQNR), which fell 2.4% and 1.4% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and oil and gas company Eni (E), which were down 1.2% and 0.9% respectively.The gainers from the UK were led by British American Tobacco (BTI) and InterContinental Hotels Group (IHG), which advanced 2.5% and 2.4% respectively. They were followed by insurance company Prudential (PUK) and educational publisher Pearson (PSO), which increased 1.2% and 0.7% respectively.The decliners from the UK and Ireland were led by biopharmaceutical firm NuCana (NCNA) and Autolus Therapeutics (AUTL), which fell 5.1% and 2.7% respectively. They were followed by Trinity Biotech (TRIB) and Silence Therapeutics (SLN), which lost 1.6% and 1% respectively.

$AUTL$BTI$CLLS$E$EQNR$EVAX$IHG$NCNA$NTZ$NVO$PSO$PUK$SAP$SLN$TRIB$UL
Sectors

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks declined Thursday afternoon, with the NYSE Health Care Index decreasing 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) fell 1.9%.In sector news, Acting Attorney General Todd Blanche signed an order Thursday reclassifying state-licensed medical cannabis as a less-dangerous drug, the Associated Press reported, citing a statement from Blanche.In corporate news, Thermo Fisher Scientific (TMO) raised its full-year outlook as Q1 results came in stronger than expected, but organic growth fell short of analysts' estimates. Shares fell 11%.Regeneron Pharmaceuticals (REGN) has struck an agreement with the Trump administration to reduce drug costs for certain Americans and has secured approval for a gene therapy to treat a rare form of deafness, Bloomberg reported. Regeneron shares rose 1.6%.Novo Nordisk (NVO) said a phase 3a trial of oral semaglutide in children and adolescents aged between 10 and 17 years with type-2 diabetes showed a "superior reduction" in a measure of blood sugar control over placebo. Shares were down 2.6%.

$NVO$REGN$TMO
Asia Markets

European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were falling sharply late Tuesday morning, dropping 1.15% to 1,812.72 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by petroleum refiner Equinor (EQNR) and internet browser company Opera (OPRA), which rose 2.7% and 1.7% respectively. They were followed by 3D printer company Materialise (MTLS) and medical device maker EDAP TMS (EDAP), which were up 1.2% each.The decliners from continental Europe were led by biopharmaceutical company argenx (ARGX) and pharmaceutical company Novo Nordisk (NVO), which fell 3% and 2.8% respectively. They were followed by biotech firm Evaxion (EVAX) and pharmaceutical company Ascendis Pharma (ASND), which were down 2.7% each.The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and software firm Endava (DAVA), which advanced 6.4% and 2.7% respectively. They were followed by education company Pearson (PSO) and pharmaceutical company Silence Therapeutics (SLN), which increased 1.2% and 0.9% respectively.The decliners from the UK and Ireland were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and NuCana (NCNA), which dropped 8.7% and 3.2% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and cruise line operator Carnival (CUK), which lost 2.3% and 2.2% respectively.

$AKTX$ARGX$ASND$BDRX$CUK$DAVA$EDAP$EQNR$EVAX$MREO$MTLS$NCNA$NVO$OPRA$PSO$SLN
Sectors

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) was fractionally higher.In corporate news, GSK (GSK) said Wednesday it has completed its $950 million acquisition of 35Pharma, adding an experimental pulmonary hypertension therapy to its respiratory, immunology and inflammation pipeline. GSK shares were down 2.1%.Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 1.1%.GoodRx (GDRX) shares climbed up 4.3% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 3.7%.Immutep (IMMP) shares surged 73% after it said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.

$GDRX$GSK$IMMP$JANX$NVO
Sectors

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.9%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Janux Therapeutics (JANX) lacks near-term stock-moving catalysts after it came under pressure following mixed results from the phase 1a trial of JANX007 in 5L metastatic prostate cancer, UBS said in a report. UBS downgraded the stock to neutral from buy and cut its price target to $15 from $57. Janux shares fell 2.9%.GoodRx (GDRX) shares climbed up 3.8% after the firm said Wednesday it is offering Novo Nordisk's (NVO) Wegovy HD 7.2 mg injectable weight loss drug to eligible self-pay patients. Novo shares rose 2.2%.Immutep (IMMP) shares doubled after the firm said the US Food and Drug Administration has granted orphan drug designation to eftilagimod alfa to treat soft tissue sarcoma, a rare cancer.

$GDRX$IMMP$JANX$NVO
Sectors

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.6%.The iShares Biotechnology ETF (IBB) climbed 2.1%.In corporate news, Johnson & Johnson (JNJ) lifted its full-year outlook on Tuesday as the healthcare products conglomerate's Q1 results surpassed Wall Street's expectations. Its shares rose 1.1%.Eli Lilly (LLY) has agreed to buy CrossBridge Bio for up to $300 million in cash, the pre-clinical biotechnology firm said Tuesday. Lilly shares were down 0.6%.Novo Nordisk (NVO) has received the Medicines and Healthcare products Regulatory Agency approval for a new single-dose 7.2 mg of Wegovy to treat adults with obesity, the UK regulator said. Novo shares climbed 3.5%.Biogen (BIIB) shares rose 1.5% after Piper Sandler upgraded the stock to overweight from neutral and boosted its price target to $214 from $177.Avanos Medical (AVNS) shares surged 69% after the company said Tuesday it agreed to be acquired by American Industrial Partners affiliates in an all-cash deal valuing the company at roughly $1.27 billion.

$AVNS$BIIB$JNJ$LLY$NVO

Showing 41-60 of 67